Enhancing poxvirus oncolytic effects through increased spread and immune evasion.
The antitumoral effects of oncolytic viruses have generally been limited by inefficient spread of the viruses within infected tumors and by inefficient systemic delivery, particularly in preimmunized hosts. Tumor-selective poxviruses have biological characteristics that may overcome these limitations. Nevertheless, physical barriers within the tumor microenvironment, including the extracellular matrix, can still limit intratumoral spread, and neutralizing antibodies can impede systemic delivery. To counter these limitations, we sought to take advantage of a naturally occurring poxvirus form known as extracellular enveloped virus (EEV). The EEV is shrouded by a host cell-derived lipid bilayer containing anticomplement proteins and is typically released from infected cells early during the infection cycle. Therefore, the EEV form evolved for rapid systemic spread within the host and for evasion of immune-mediated clearance. We compared the oncolytic potential of low versus high EEV-producing strains of vaccinia. EEV-enhanced vaccinia strains displayed improved spread within tumors after systemic delivery, resulting in significantly improved antitumor effects. The EEV-enhanced strains also displayed a greater ability to spread between injected and noninjected distant tumors through the blood and, importantly, displayed reduced clearance by neutralizing antibody. Safety was unaffected. The incorporation of EEV-enhancing mutations into next generation oncolytic vaccinia strains may improve the potency of these viruses without sacrificing safety.
Kirn
David H
DH
Jennerex Biotherapeutics, Ltd., San Francisco, California, USA.
Wang
Yaohe
Y
Liang
Wenchung
W
Contag
Christopher H
CH
Thorne
Stephen H
SH
D000818:Animals; D045744:Cell Line, Tumor; D005260:Female; D006801:Humans; D008051:Lipid Bilayers / Q000276:immunology; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D009369:Neoplasms / Q000276:immunology / Q000628:therapy* / Q000821:virology; D050130:Oncolytic Virotherapy / Q000379:methods*; D014616:Vaccinia virus / Q000235:genetics / Q000276:immunology / Q000502:physiology*; D014759:Viral Envelope Proteins / Q000276:immunology
D008051:Lipid Bilayers; D014759:Viral Envelope Proteins